Leukocyte interferon-α and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon-Reference-Cited by-同舟云学术

Leukocyte interferon-α and ribavirin for treatment of chronic hepatitis C patients intolerant to pegylated-interferon

Published:2009-08-01 Issue:6 Volume:4 Page:485-490
ISSN:1828-0447
Container-title:Internal and Emergency Medicine
language:en
Short-container-title:Intern Emerg Med

Author:

Adinolfi Luigi E.,Durante-Mangoni Emanuele,Salzillo Marta,Marrone Aldo,Tripodi Marie-Francoise,Restivo Luciano,Merola Antonietta,Zampino Rosa,Ruggiero Giuseppe

Publisher

Springer Science and Business Media LLC

Subject

Emergency Medicine,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s11739-009-0290-z.pdf

Reference17 articles.

1. Hoofnagle JH, Seef LB (2006) Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355:2444–2451

2. Manns MP, McHutchison JG, Gordon SC et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965

3. Fried MW, Shiffmann ML, Reddy KR et al (2002) Combination of peginterferon alfa-2a plus ribavirin in patients with chronic hepatitis C virus infection. N Engl J Med 347:975–982

4. Hadziyannis SJ, Sette H Jr, Morgan TR et al (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346–355

5. McHutchison JG, Manns M, Patel K et al (2002) Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123:1061–1069

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience;Infection;2011-07-08

2. Antiviral Information Management System (AIMS): A Prototype for Operational Innovation in Drug Development;The Journal of Clinical Pharmacology;2010-09